The relationship between islet autoantibody status and the genetic risk of type 1 diabetes in adult-onset type 1 diabetes
Aims/hypothesis The reason for the observed lower rate of islet autoantibody positivity in clinician-diagnosed adult-onset vs childhood-onset type 1 diabetes is not known. We aimed to explore this by assessing the genetic risk of type 1 diabetes in autoantibody-negative and -positive children and adults. Methods We analysed GAD autoantibodies, insulinoma-2 antigen autoantibodies and zinc transporter-8 autoantibodies (ZnT8A) and measured type 1 diabetes genetic risk by genotyping 30 type 1 diabetes-associated variants at diagnosis in 1814 individuals with clinician-diagnosed type 1 diabetes (1112 adult-onset, 702 childhood-onset). We compared the overall type 1 diabetes genetic risk score (T1DGRS) and non-HLA and HLA (DR3-DQ2, DR4-DQ8 and DR15-DQ6) components with autoantibody status in those with adult-onset and childhood-onset diabetes. We also measured the T1DGRS in 1924 individuals with type 2 diabetes from the Wellcome Trust Case Control Consortium to represent non-autoimmune diabetes control participants. Results The T1DGRS was similar in autoantibody-negative and autoantibody-positive clinician-diagnosed childhood-onset type 1 diabetes (mean [SD] 0.274 [0.034] vs 0.277 [0.026], p=0.4). In contrast, the T1DGRS in autoantibody-negative adult-onset type 1 diabetes was lower than that in autoantibody-positive adult-onset type 1 diabetes (mean [SD] 0.243 [0.036] vs 0.271 [0.026], p<0.0001) but higher than that in type 2 diabetes (mean [SD] 0.229 [0.034], p<0.0001). Autoantibody-negative adults were more likely to have the more protective HLA DR15-DQ6 genotype (15% vs 3%, p<0.0001), were less likely to have the high-risk HLA DR3-DQ2/DR4-DQ8 genotype (6% vs 19%, p<0.0001) and had a lower non-HLA T1DGRS (p<0.0001) than autoantibody-positive adults. In contrast to children, autoantibody-negative adults were more likely to be male (75% vs 59%), had a higher BMI (27 vs 24 kg/$ m^{2} $) and were less likely to have other autoimmune conditions (2% vs 10%) than autoantibody-positive adults (all p<0.0001). In both adults and children, type 1 diabetes genetic risk was unaffected by the number of autoantibodies (p>0.3). These findings, along with the identification of seven misclassified adults with monogenic diabetes among autoantibody-negative adults and the results of a sensitivity analysis with and without measurement of ZnT8A, suggest that the intermediate type 1 diabetes genetic risk in autoantibody-negative adults is more likely to be explained by the inclusion of misclassified non-autoimmune diabetes (estimated to represent 67% of all antibody-negative adults, 95% CI 61%, 73%) than by the presence of unmeasured autoantibodies or by a discrete form of diabetes. When these estimated individuals with non-autoimmune diabetes were adjusted for, the prevalence of autoantibody positivity in adult-onset type 1 diabetes was similar to that in children (93% vs 91%, p=0.4). Conclusions/interpretation The inclusion of non-autoimmune diabetes is the most likely explanation for the observed lower rate of autoantibody positivity in clinician-diagnosed adult-onset type 1 diabetes. Our data support the utility of islet autoantibody measurement in clinician-suspected adult-onset type 1 diabetes in routine clinical practice. Graphical abstract.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
---|---|
Enthalten in: |
Diabetologia - 66(2022), 2 vom: 10. Nov., Seite 310-320 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Thomas, Nicholas J. [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Adult onset |
---|
RVK: |
---|
Anmerkungen: |
© The Author(s) 2022 |
---|
doi: |
10.1007/s00125-022-05823-1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2080209086 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2080209086 | ||
003 | DE-627 | ||
005 | 20230516013354.0 | ||
007 | tu | ||
008 | 230131s2022 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s00125-022-05823-1 |2 doi | |
035 | |a (DE-627)OLC2080209086 | ||
035 | |a (DE-He213)s00125-022-05823-1-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
082 | 0 | 4 | |a 610 |q VZ |
084 | |a XA 40615 |q VZ |2 rvk | ||
100 | 1 | |a Thomas, Nicholas J. |e verfasserin |0 (orcid)0000-0003-2513-7022 |4 aut | |
245 | 1 | 0 | |a The relationship between islet autoantibody status and the genetic risk of type 1 diabetes in adult-onset type 1 diabetes |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © The Author(s) 2022 | ||
520 | |a Aims/hypothesis The reason for the observed lower rate of islet autoantibody positivity in clinician-diagnosed adult-onset vs childhood-onset type 1 diabetes is not known. We aimed to explore this by assessing the genetic risk of type 1 diabetes in autoantibody-negative and -positive children and adults. Methods We analysed GAD autoantibodies, insulinoma-2 antigen autoantibodies and zinc transporter-8 autoantibodies (ZnT8A) and measured type 1 diabetes genetic risk by genotyping 30 type 1 diabetes-associated variants at diagnosis in 1814 individuals with clinician-diagnosed type 1 diabetes (1112 adult-onset, 702 childhood-onset). We compared the overall type 1 diabetes genetic risk score (T1DGRS) and non-HLA and HLA (DR3-DQ2, DR4-DQ8 and DR15-DQ6) components with autoantibody status in those with adult-onset and childhood-onset diabetes. We also measured the T1DGRS in 1924 individuals with type 2 diabetes from the Wellcome Trust Case Control Consortium to represent non-autoimmune diabetes control participants. Results The T1DGRS was similar in autoantibody-negative and autoantibody-positive clinician-diagnosed childhood-onset type 1 diabetes (mean [SD] 0.274 [0.034] vs 0.277 [0.026], p=0.4). In contrast, the T1DGRS in autoantibody-negative adult-onset type 1 diabetes was lower than that in autoantibody-positive adult-onset type 1 diabetes (mean [SD] 0.243 [0.036] vs 0.271 [0.026], p<0.0001) but higher than that in type 2 diabetes (mean [SD] 0.229 [0.034], p<0.0001). Autoantibody-negative adults were more likely to have the more protective HLA DR15-DQ6 genotype (15% vs 3%, p<0.0001), were less likely to have the high-risk HLA DR3-DQ2/DR4-DQ8 genotype (6% vs 19%, p<0.0001) and had a lower non-HLA T1DGRS (p<0.0001) than autoantibody-positive adults. In contrast to children, autoantibody-negative adults were more likely to be male (75% vs 59%), had a higher BMI (27 vs 24 kg/$ m^{2} $) and were less likely to have other autoimmune conditions (2% vs 10%) than autoantibody-positive adults (all p<0.0001). In both adults and children, type 1 diabetes genetic risk was unaffected by the number of autoantibodies (p>0.3). These findings, along with the identification of seven misclassified adults with monogenic diabetes among autoantibody-negative adults and the results of a sensitivity analysis with and without measurement of ZnT8A, suggest that the intermediate type 1 diabetes genetic risk in autoantibody-negative adults is more likely to be explained by the inclusion of misclassified non-autoimmune diabetes (estimated to represent 67% of all antibody-negative adults, 95% CI 61%, 73%) than by the presence of unmeasured autoantibodies or by a discrete form of diabetes. When these estimated individuals with non-autoimmune diabetes were adjusted for, the prevalence of autoantibody positivity in adult-onset type 1 diabetes was similar to that in children (93% vs 91%, p=0.4). Conclusions/interpretation The inclusion of non-autoimmune diabetes is the most likely explanation for the observed lower rate of autoantibody positivity in clinician-diagnosed adult-onset type 1 diabetes. Our data support the utility of islet autoantibody measurement in clinician-suspected adult-onset type 1 diabetes in routine clinical practice. Graphical abstract | ||
650 | 4 | |a Adult onset | |
650 | 4 | |a Diabetes classification | |
650 | 4 | |a Islet autoantibodies | |
650 | 4 | |a Type 1 diabetes | |
650 | 4 | |a Type 2 diabetes | |
700 | 1 | |a Walkey, Helen C. |0 (orcid)0000-0003-3391-0759 |4 aut | |
700 | 1 | |a Kaur, Akaal |4 aut | |
700 | 1 | |a Misra, Shivani |0 (orcid)0000-0003-2886-0726 |4 aut | |
700 | 1 | |a Oliver, Nick S. |0 (orcid)0000-0003-3525-3633 |4 aut | |
700 | 1 | |a Colclough, Kevin |0 (orcid)0000-0003-0566-4853 |4 aut | |
700 | 1 | |a Weedon, Michael N. |0 (orcid)0000-0002-6174-6135 |4 aut | |
700 | 1 | |a Johnston, Desmond G. |0 (orcid)0000-0001-9539-7108 |4 aut | |
700 | 1 | |a Hattersley, Andrew T. |0 (orcid)0000-0001-5620-473X |4 aut | |
700 | 1 | |a Patel, Kashyap A. |0 (orcid)0000-0002-9240-8104 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Diabetologia |d Springer Berlin Heidelberg, 1965 |g 66(2022), 2 vom: 10. Nov., Seite 310-320 |w (DE-627)129069140 |w (DE-600)1694-9 |w (DE-576)014400847 |x 0012-186X |7 nnns |
773 | 1 | 8 | |g volume:66 |g year:2022 |g number:2 |g day:10 |g month:11 |g pages:310-320 |
856 | 4 | 1 | |u https://doi.org/10.1007/s00125-022-05823-1 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a GBV_ILN_267 | ||
912 | |a GBV_ILN_2018 | ||
912 | |a GBV_ILN_4277 | ||
936 | r | v | |a XA 40615 |
951 | |a AR | ||
952 | |d 66 |j 2022 |e 2 |b 10 |c 11 |h 310-320 |